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Objectives This study investigated the hypothesis whether S100A1 gene therapy can improve pathological key features in
human failing ventricular cardiomyocytes (HFCMs).
Background Depletion of the Ca2-sensor protein S100A1 drives deterioration of cardiac performance toward heart failure
(HF) in experimental animal models. Targeted repair of this molecular defect by cardiac-specific S100A1 gene
therapy rescued cardiac performance, raising the immanent question of its effects in human failing myocardium.
Methods Enzymatically isolated HFCMs from hearts with severe systolic HF were subjected to S100A1 and control adeno-
viral gene transfer and contractile performance, calcium handling, signaling, and energy homeostasis were ana-
lyzed by video-edge-detection, FURA2-based epifluorescent microscopy, phosphorylation site-specific antibodies,
and mitochondrial assays, respectively.
Results Genetically targeted therapy employing the human S100A1 cDNA normalized decreased S100A1 protein levels
in HFCMs, reversed both contractile dysfunction and negative force-frequency relationship, and improved con-
tractile reserve under beta-adrenergic receptor (-AR) stimulation independent of cAMP-dependent (PKA) and
calmodulin-dependent (CaMKII) kinase activity. S100A1 reversed underlying Ca2 handling abnormalities basally
and under -AR stimulation shown by improved SR Ca2 handling, intracellular Ca2 transients, diastolic
Ca2 overload, and diminished susceptibility to arrhythmogenic SR Ca2 leak, respectively. Moreover,
S100A1 ameliorated compromised mitochondrial function and restored the phosphocreatine/adenosine-
triphosphate ratio.
Conclusions Our results demonstrate for the first time the therapeutic efficacy of genetically reconstituted S100A1 protein
levels in HFCMs by reversing pathophysiological features that characterize human failing myocardium. Our find-
ings close a gap in our understanding of S100A1’s effects in human cardiomyocytes and strengthen the ratio-
nale for future molecular-guided therapy of human HF. (J Am Coll Cardiol 2011;58:966–73) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.03.054Heart failure (HF) remains a major cause of morbidity and
mortality (1), and a currently unmet need for novel thera-
peutic strategies requires clinically applicable treatment
options targeting the underlying molecular causes of the
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August 23, 2011:966–73 S100A1 Gene Therapy of Failing Human Myocardiumdisease. A promising innovation entering the clinical
stage is genetically targeted therapy of human HF (2).
Ongoing early stage phase I/II human clinical trials by
Hajjar et al. (3) determined safety and therapeutic efficacy
of gene-based restoration of an enzyme improving cardi-
omyocyte Ca2 handling in patients with advanced HF.
hese studies, therefore, pave the way for the develop-
ent of molecular-guided treatments for HF aiming at
he roots of the disease.
The EF-hand Ca2-sensor protein S100A1 has emerged
s an attractive target for genetically targeted HF therapy
ecause the association between decreased S100A1 expres-
ion in cardiomyocytes and the progression to systolic HF
as been well documented. Translational studies in small-
nd large-animal HF models identified S100A1 as a
nique regulator of an integrative and Ca2-controlled
network in cardiomyocytes improving sarcoplasmic retic-
ulum (SR), sarcomeric, and mitochondrial function (re-
viewed in Rohde et al. [4]). Comprehensive actions of
S100A1 are modulation of ryanodine receptor (RyR2),
SR Ca2-ATPase (SERCA2), cardiac titin, and mito-
hondrial F1-ATPase activity (5–9). As a result, hearts
ith increased S100A1 expression exhibit superior sys-
olic and diastolic performance (6,10,11), as well as
itochondrial high-energy phosphate generation (8,9),
hereas mice with cardiac S100A1 deficiency show
ccelerated HF and fatal arrhythmias in response to
hronic hemodynamic stress and ischemic damage (12–
5). Mechanistically, S100A1 improves cardiomyocyte
erformance by augmenting Ca2 transient amplitudes
nd decreasing diastolic Ca2 overload based on in-
creased Ca2-induced SR Ca2 release together with
decreased diastolic SR Ca2 leak and accelerated Ca2
resequestration (5–11,14,16).
Preclinical studies have clearly documented the associa-
tion of decreased cardiomyocyte S100A1 expression with
HF and show that S100A1 gene-targeted therapy reversed
experimental HF and improved cardiac performance in
small and large animal studies (17,18).
This study investigates restoration of S100A1 expression
in human isolated cardiomyocytes, revealing improved path-
ological key features of human failing myocardium and
phenotyping the molecular and cellular effects of targeted
S100A1 gene therapy for the first time in a valuable in vitro
model of human systolic HF. Our findings close a gap in the
current knowledge of ways in which S100A1 modifies
several molecular endpoints of HFCMs, and further trans-
lation might pave the way for S100A1 genetically targeted
human HF therapy.
Materials and Methods
Human ventricular myocardium was obtained from 27
patients with severe ischemic systolic HF undergoing heart
transplantation. Protocols for cardiomyocyte isolation, gen-
eration of the adenovirus used to express S100A1 incultured HFCMs, analysis of
cardiomyocyte contractility and
Ca2 handling, RNA and pro-
tein expression, SR Ca2 fluxes,
itochondrial function, and
igh-energy metabolites are de-
ailed extensively in the Online
ppendix. Results are presented
s mean  SEM. Comparisons
between treatment groups were
made using unpaired 2-tailed
Student t test and analysis of vari-
ance followed by the Student-
Newman-Keuls method for post
hoc analysis. Fisher exact test was
used to compare percentage of
diastolic Ca2 waves between
groups by comparing paced car-
diomyocytes without, to cardio-
myocytes with diastolic Ca2
waves. For all tests, a probability
value 0.05 was considered sig-
nificant.
Results
Genetically targeted therapy reconstitutes S100A1
expression in human failing cardiomyocytes. S100A1 pro-
tein and mRNA levels were decreased in ischemic cardio-
myopathy by 3.5-fold (Fig. 1A) and 5.0-fold (data not
shown), respectively, compared with healthy normal myo-
cardium. These findings suggest that abnormal transcrip-
tional regulation causes aberrant S100A1 protein expression
in advanced stages of HF, and corroborate earlier results by
Remppis et al. (19). Human S100A1 cDNA was delivered
to isolated HFCMs by adenoviral infection (Ad-S100A1),
resulting in significantly enhanced S100A1 protein levels 24
h after transfection (Fig. 1B) (3.2-fold, p  0.05, n  5).
ur in vitro gene therapy protocol apparently restored
100A1 protein levels to approximately normal levels in
FCMs, whereas the Ad-GFP control virus did not change
iminished S100A1 protein levels (Fig. 1B). Expression of
ther Ca2-handling proteins in HFCMs, such as down-
regulated SERCA2a and increased NCX were unchanged
(Online Fig. 1).
S100A1 gene replacement improves contractility and
reverses negative force-frequency relation. HFCMs with
restored S100A1 protein levels showed significant improve-
ment of fractional shortening (FS) (Figs. 2A and 2B) at all
tested frequencies (0.2 to 2 Hz), indicating concurrent
enhancement of systolic and diastolic function compared
with control cells. Normalization of S100A1 even reversed
the negative force-frequency response (FFR) seen in control
HFCMs, which is a hallmark of human failing hearts (20).
Abbreviations
and Acronyms
-AR  beta-adrenergic
receptor
Ad  adenoviral
CaMKII  calmodulin-
dependent protein kinase II
FFR  force-frequency
response
FS  fractional shortening
HF  heart failure
HFCM  human failing
cardiomyocyte
PC/ATP 
phosphocreatine/
adenosine-triphosphate
PKA  cAMP-dependent
protein kinase A
RyR2  Ryanodine
Receptor 2
SERCA2  Sarcoplasmic
Reticulum Ca2 ATPase 2
SR  sarcoplasmic
reticulumIn vitro S100A1 therapeutic effects were most prominent at
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S100A1 Gene Therapy of Failing Human Myocardium August 23, 2011:966–731 and 2 Hz, reflecting clinically relevant human heart rates
in vivo (Figs. 2A and 2B).
S100A1 gene-based therapy improves cellular Ca2 handling
and SRCa2 load in HFCMs. Ca2measurements in field-
timulated HFCMs revealed significantly increased systolic
a2 transient amplitudes (control 152  31 nmol/l vs.
S100A1 389  45 nmol/l, p  0.05) and enhanced SR
Ca2 load (control 314  22 nmol/l vs. S100A1 468  36
nmol/l, p  0.05) in S100A1-treated cells (Figs. 3A and
3B). Accordingly, diastolic cytosolic Ca2 concentrations
control 302  44 nmol/l vs. S100A1 187  16 nmol/l,
p  0.05) and the normalized Ca2 50% transient decay
control 413  23 ms vs. S100A1 301  24 ms, p  0.05)
were significantly lower in S100A1-expressing HFCMs,
which was accompanied by significantly greater enzymatic
SERCA2 activity (1.51-fold vs. control HFCMs, p 
0.05) (Online Fig. 2). In SR vesicles treated with 100 nmol/l
hrS100A1 protein (p  0.05 vs. vehicle; n  5), which was
associated with a 2.1-fold significantly enhanced S100A1/
SERCA2 interaction (Online Fig. 3), Ca2 uptake and
Ca2 ATPase activity improved by 1.9- and 2.4-fold,
respectively. Overall, these data point toward a direct effect
of S100A1 on SERCA2 to stimulate accelerated SR Ca2
resequestration and improve diastolic function in HFCMs.
S100A1 improves contractile reservemechanisms independent
of cAMP-dependent and calmodulin-dependent kinase
activity. In light of previous studies showing preserved
effects of S100A1 in failing myocardium with concurrent
Figure 1 Diminished S100A1 Expression in End-Stage Human F
(A) Significantly diminished S100A1 protein levels in left ventricular myocardium f
 SEM) compared with normal myocardial (NM) samples (p  0.05 vs. NM; n  4
HFCMs to levels seen in normal myocardium by adenoviral-mediated gene transfer
S100A1 cDNA) and Ad-control–transfected cells. Ad  adenoviral; CSQ  calsequ
diomyocyte; ICM  ischemic cardiomyopathy.beta-adrenergic receptor (-AR) stimulation, we deter-mined Ca2 handling in the presence of the -AR agonist
isoproterenol. As shown in Figures 4A and 4B, -AR–
stimulated S100A1-expressing HFCMs exhibited a signif-
icantly greater relative increase in systolic Ca2 transient
amplitudes (S100A1 52  4% vs. control 23  6%, p 
0.05) and preserved gain in SR Ca2 load over controls
nmol/l; control 367 35 vs. S100A1 551 39, p 0.05).
espite increased -AR responsiveness, subsequent analysis
of downstream cAMP-dependent protein kinase A (PKA)
and calmodulin-dependent protein kinase II (CaMKII)
activity revealed a similar increase in phosphorylation levels
of phospholamban (PLB) in S100A1-expressing and con-
trol HFCMs from equal baseline phosphorylation (relative
n-fold increase; PLB-ser 16/PLB 2.1  0.4 S100A1 vs.
2.2  0.6 control, p  NS; PLB-thr 17/PLB 1.7  0.6
S100A1 vs. 1.8  0.5 control, p  NS) (Figs. 5A and
5B). These results indicate that S100A1 therapeutic effects
under basal and -AR stimulation, at least on diastolic SR
Ca2 uptake, do not emanate from altered PKA and
aMKII activity.
100A1 genetically targeted therapy prevents arrhythmogenic
R Ca2 leak in HFCMs. Given the risk of arrhythmo-
enic Ca2 leak by reloading the SR with Ca2, we assessed
hether S100A1 effects render HFCMs susceptible to
iastolic Ca2 wave formation. Eighty percent (20 of 25) of
ontrol but only 13% (3 of 25) of S100A1-expressing field-
timulated (2 Hz) HFCMs exhibited diastolic Ca2 waves in
esponse to -AR stimulation (Fig. 6A) ( p 0.05 control vs.
Myocardium Is Reconstituted by S100A1 Gene Therapy
man failing hearts with severe systolic failure (ejection fraction 18  9%, mean
s. HF ICM n  23). (B) S100A1 protein levels can be restored in left ventricular
n by a green fluorescent reporter gene expression within Ad-S100A1 (human
GFP  green fluorescent protein; HF  heart failure; HFCM  human failing car-ailing
rom hu
NM v
show
estrin;S100A1), indicating protection from a potential arrhythmo-
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August 23, 2011:966–73 S100A1 Gene Therapy of Failing Human Myocardiumgenic substrate for delayed after-depolarization (21). The
protective effect of S100A1 in HFCMs was associated with
augmented binding to the human RyR2 (S100A1/RyR2
ratio; control 0.42  0.11 vs. S100A1 0.86  0.16, p 
.05) (Fig. 6B) and occurred despite a significantly higher
R Ca2 load than control cells (Fig. 4B). Enhanced
S100A1/RyR2 interaction (S100A1/RyR2 ratio; control
0.42 0.11 vs. S100A10.86 0.16, p 0.05) in treated
SR vesicles suggests a direct inhibitory effect of S100A1 on
RyR2 dysfunction, given a 2.8-fold decrease in Ca2 leak
from S100A1-treated SR vesicles (Online Fig. 3).
Compromised energy homeostasis and mitochondrial
function in HFCMs is ameliorated through S100A1 gene
replacement. Since elevated diastolic Ca2 levels and SR
Ca2 leak can disturb cardiomyocyte energy homeostasis
(22), we assessed the impact of S100A1 on high-energy
phosphate content. The phosphocreatine/adenosine-
triphosphate (PC/ATP) ratio was significantly elevated after
S100A1 gene delivery (2.4  0.05) to previously published
near-normal levels (5,23) as opposed to control with a ratio
of 1.1  0.2 (p  0.05 vs. S100A1) (Fig. 7A). Functional
nalysis of isolated mitochondria from S100A1-expressing
Figure 2 S100A1 Improves Contractile Performance
and Reverses the Negative FFR in HFCM
(A) Representative steady-state twitches for control (Ad-control) and S100A1-
treated (Ad-S100A1) human failing cardiomyocytes (HFCMs) ranging from 0.2
to 2 Hz illustrate (B) restoration of a positive FFR and significantly enhanced
FS by S100A1 at all tested frequencies compared with controls. Asterisks cor-
respond to comparisons between 0.2 and 2 Hz values for control and S100A1-
treated cells. Ad  adenoviral; FFR  force-frequency response; FS 
fractional shortening.FCMs revealed superior electron flow even under Ca2stress (Fig. 7B) and enhanced mitochondrial S100A1 pro-
tein content (Online Figure 4) compared with controls.
S100A1 restoration in HFCMs was further accompanied by
preserved m basally and in response to Ca2 treatment
Online Fig. 5). Isolated mitochondria from S100A1-
xpressing HFCMs further unveiled diminished suscepti-
ility to mitochondrial permeability transition in response to
xperimental Ca2 overload and phosphate stress (Online
ig. 6). Overall, these findings suggest a potentially direct
ffect of S100A1 and further corroborate S100A1’s benefi-
ial actions on mitochondrial function and energy homeo-
tasis in HFCMs.
iscussion
his study shows the profound effects of S100A1 geneti-
ally targeted therapy in HFCMs and translates previous
echanistic and therapeutic findings in animal HF models
owards S100A1 gene-based treatment of human failing
yocardium in vitro (for synopsis, see Online Fig. 7).
herapeutic efficacy of restored S100A1 protein expression
n human HF. A key feature of HF seems to be depletion
f S100A1 in cardiomyocytes, which results in defective
ntracellular Ca2 cycling and poor contractility (4). Our
Figure 3 S100A1 Restores Ca
2 Handling in
Failing Human Myocardium
(A) Representative Ca2 transients and corresponding normalized transient
decays under basal conditions from Ad-control–treated (red line) and
Ad-S100A1–treated (green line) HFCMs paced at 1 Hz depict enhanced Ca2
transient amplitudes and accelerated cytosolic Ca2 removal by S100A1.
(B) Representative tracings of caffeine-induced (10 mmol/l pulse) rise in cyto-
solic Ca2 illustrates a greater amplitude in Ad-S100A1–treated cells (red line)
compared with control cells (green line) reflecting enhanced SR Ca2 load by
S100A1. SR  sarcoplasmic reticulum; other abbreviations as in Figure 1.
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S100A1 Gene Therapy of Failing Human Myocardium August 23, 2011:966–73study shows that therapeutic actions of S100A1 in HFCMs
might require only modest changes in S100A1 expression
obtainable by myocardial-targeted, viral-based gene addi-
tion. Sustained therapeutic consequences of similarly mod-
est changes in cardiomyocyte S100A1 expression in various
experimental HF models (3,4) prompt speculation that even
a moderate S100A1 gene dosage may achieve therapeuti-
cally effective changes in human failing myocardium in vivo.
Further proof of in vitro therapeutic efficacy stems from the
observation that S100A1 can rescue defective SR function
and Ca2 handling in HFCMs despite continued abnor-
alities in the expression of key sarcoplasmic (SERCA2)
nd sarcolemmal (NCX) Ca2-regulator proteins. Similar
ndings in experimental HF (5,17,18) corroborate the
otion that S100A1 neither requires nor depends on nor-
alized SERCA2 and NCX expression, at least for acute
herapeutic actions in vitro.
ey role of restored SR function and Ca2 homeostasis.
he SR is critical in the regulation of human cardiomyocyte
a2 homeostasis (24). S100A1 seems capable of restoring
R function in HFCMs, which is most likely key to
Figure 4 S100A1 Improves Contractile Reserve
Mechanisms in Failing Human Myocardium
(A) Representative Ca2 transients and corresponding normalized transient
decays from an isoproterenol-stimulated FURA2-AM loaded Ad-control–treated
(red line) and Ad-S100A1–treated (green line) HFCM illustrate preserved gain-
in-function, enhanced Ca2 transient amplitude, and accelerated cytosolic
Ca2 removal by S100A1 in response to -AR stimulation. (B) Representative
tracings of caffeine-induced (10 mmol/l pulse) rise in cytosolic Ca2 depicts a
greater amplitude in -AR–stimulated Ad-S100A1–treated cells (green line)
compared with control cells (red line) reflecting increased SR Ca2 load.
Abbreviations as in Figures 1 and 3.mproved systolic SR Ca2 release being translated intougmented intracellular Ca2 transients with accelerated
emoval of cytosolic Ca2 and reversal of diastolic Ca2
overload. These results are in line with previously charac-
terized molecular mechanisms in animal HF models relating
S100A1 salutary actions to improved RyR2 and SERCA2
function with subsequent rescue of systolic and diastolic
contractile function, prevention of arrhythmogenic Ca2
leak, and ameliorated energy homeostasis (5,6,10,14,17,25).
Therapeutic impact on contractile dysfunction. The
ability of the SR to transport larger amounts of Ca2
appears critical for frequency-dependent enhancement in
contractile strength (20). Hence, reversal of the negative
FFR in HFCMs may be attributed to S100A1-mediated
frequency-dependent improvement of SR Ca2 load and,
ubsequently, augmented intracellular systolic Ca2 tran-
ient amplitudes. Of note, the S100A1-mediated effect on
eak systolic Ca2 levels did not prolong relaxation but
rather improved diastolic function despite persistent abnor-
malities in SERCA2 and NCX expression, likely due to its
concurrent impact on diastolic SR Ca2 uptake in HFCMs.
The latter indicates that a previously described interaction
of S100A1 with SERCA2 both in human (7) and rodent
myocardium (5,10) might actually reflect a relevant stimulus
of diastolic SR Ca2 resequestration.
The therapeutic effect of S100A1 on contractile perfor-
ance of HFCMs appeared most prominent at frequencies
Figure 5 S100A1 Functions Independently of PKA
and CaMKII in Human Failing Myocardium
Shown by representative immunoblots of phosphorylated phospholamban at
serine 16 (PLB-ser 16) (A) and threonine 17 (PLB-thr 17) (B), S100A1 gene-
based therapy changes neither PKA- nor CaMKII-dependent signaling down-
stream of -ARs in HFCMs under basal conditions or isoproterenol stimulation.
-AR  -adrenergic receptor; CaMKII  calmodulin dependent kinase II;
cAMP  cyclic adenosine monophosphate; HFCM  human failing cardiomyo-
cyte; PKA  protein kinase A.
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August 23, 2011:966–73 S100A1 Gene Therapy of Failing Human Myocardiumapproximating actual beating rates of normal and diseased
human hearts (60 to 120 beats/min). Since rodent myocar-
dium per se exhibits a negative contractile response at
human heart rates (26) and does not faithfully mirror the
human phenotype with respect to Ca2 handling, discovery
f this potentially relevant in vitro therapeutic effect is
ependent on the use of HFCMs.
Figure 6 S100A1 Interacts With Human RyR2
and Prevents Arrhythmogenic SR Ca2 Leak
(A) Representative tracings of Ca2 transients in an isoproterenol/caffeine-
stimulated control (Ad-control) and S100A1-treated (Ad-S100A1) HFCM illus-
trate the protective effect of S100A1 against -AR–triggered diastolic SR Ca2
leak (asterisks). (B) S100A1 interaction with the RyR2 is enhanced after
S100A1 gene-based therapy (Ad-S100A1) compared with control (Ad-control).
IB  immunoblot; IP  immunoprecipitation; other abbreviations as in
Figures 1, 3, and 5.
Figure 7 S100A1 Ameliorates Abnormal High-Energy Phosphat
(A) Normalization of S100A1 in HFCMs resulted in a restored PC/ATP ratio reflect
mitochondria from S100A1-expressing HFCMs under basal conditions (buffer) a
Abbreviations as in Figure 1.revention of arrhythmogenic SR Ca2 leak by S100A1
gene-based therapy. A potentially fatal side effect of drugs
or molecular interventions that reload the SR with Ca2,
such as -AR agonists, is arrhythmogenic diastolic Ca2
leak (21). Our data show that S100A1 effectively prevents
diastolic Ca2 wave formation in experimentally forced SR
Ca2 leakage despite enhanced SR Ca2load. Increased
S100A1 interaction with the RyR2 under these conditions
prompts speculation that it directly modulates RyR2 dia-
stolic function, because similar findings in animal HF
models corroborate these data (5,6,10,14,17,25). Thus,
although the molecular mechanism remains to be deter-
mined, S100A1 seems to be a unique molecular therapeutic
with respect to SR Ca2 handling, potentially superior to
-AR inotropic agonists by combining enhanced contractile
function with prevention of arrhythmogenic Ca2 leak.
-AR–independent improvement of contractile reserve.
The S100A1-mediated gain in contractile performance and
SR Ca2 handling in HFCMs was preserved under -AR
timulation and, subsequently, improved -AR reserve.
Further investigation of putative downstream signaling
seems to suggest that S100A1 therapeutic actions under
basal and stimulated conditions in HFCMs neither depend
on nor include detrimental and pro-arrhythmogenic PKA
and CaMKII activity. This is in line with previous studies
showing that S100A1-mediated improvement of cardiac
function in experimental HF models is additive to stimula-
tion with -AR agonists but independent of downstream
PKA and CaMKII activity (5,6,10,14,17,18). These find-
ings support the notion that targeted S100A1 restoration in
failing myocardium acts synergistically with catecholamine
therapy and could even lower the dosage and duration of
toxic, pro-arrhythmogenic cAMP-targeted therapies in sys-
tent and Mitochondrial Electron Flow in HFCMs
eliorated cellular energy homeostasis. (B) Superior electron flow in isolated
perimental Ca2 stress (CaCl2 100 mol/l) as assessed by MTT reduction.e Con
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S100A1 Gene Therapy of Failing Human Myocardium August 23, 2011:966–73tolic HF. These issues are the subject of ongoing
investigations.
Amelioration of aberrant cardiomyocyte energy homeostasis.
Defects in cardiomyocyte Ca2 handling such as diastolic
Ca2 overload can adversely affect mitochondrial integrity,
nitiating a vicious cycle of contractile dysfunction and
igh-energy phosphate depletion (22). Normalization of
100A1 protein in HFCMs restored the depressed PC/
TP ratio to previously reported normal values in human
earts (23). The improvement of PC/ATP, being an inde-
endent predictor of cardiovascular mortality (23), might be
n part the result of reconstituted diastolic Ca2 handling as
previously shown by S100A1 gene therapy in experimental
HF models (5). Our results further unveil improved electron
flow and m, as well as protection from mitochondrial
permeability transition under experimental Ca2 stress in
itochondria either treated with S100A1 or isolated from
100A1-expressing HFCMs. These findings support the
otion that S100A1’s previously reported interaction with
itochondrial proteins in the inner and outer matrix such as
socitrate dehydrogenase, F1-ATPase, and adenine nucleo-
ide translocator, among others (9), might be of therapeutic
elevance and mechanistically contribute to restoration of
he PC/ATP ratio. Hence, it is tempting to speculate that
ffects on diastolic Ca2 levels as well as direct modulation
of mitochondrial targets through S100A1 each account in
part for preserved mitochondrial function and restoration of
HFCM energy homeostasis. However, further studies are
clearly needed delineating underlying molecular mecha-
nisms as well as the potential route of mitochondrial uptake
for S100A1.
Study limitations. Our approach testing therapeutic ac-
tions of S100A1 in HFCMs has advantages over isolated
cardiomyocytes from small-animal HF models due to fun-
damental differences in cellular Ca2 handling compared
with human cardiomyocytes. However, neither can our in
vitro results readily be extrapolated to the intact organ nor
predict outcome of S100A1 genetically targeted therapies in
human failing hearts under clinical conditions. Moreover,
absence of mechanical load can significantly alter signaling and
contractile characteristics, and most importantly, therapeutic
effects of molecular interventions in isolated cardiomyocytes.
Future studies employing loaded human trabecular muscle
fibers or muscle strips isolated from failing hearts might be
desirable to determine S100A1’s impact under isometric stress.
Clinical implications. Our study demonstrates that mod-
est changes of S100A1 protein by genetically targeted gene
addition are actually therapeutic in failing human myocar-
dium in vitro. The unique molecular profile of S100A1
originates from reversing clinically relevant key features in
HFCMs. S100A1 might, therefore, enable long-term ther-
apy of human failing myocardium without pro-arrhythmic
side effects and increased energy consumption typically seen
with the use of conventional inotropic agents such as
sympathomimetic agents and phosphodiesterase inhibitors.
Given the proven therapeutic efficacy of S100A1 in pre-clinical studies, these findings might well present the ratio-
nale for a new treatment targeting a key deficiency in
advanced human HF. Since synergistic effects of S100A1
with -AR blockers were observed in experimental HF (4),
t is tempting to speculate that future targeted S100A1 gene
herapy may complement conventional drug regimens for
ystolic HF treatment.
onclusions
his study is the first to document the therapeutic effec-
iveness of restored S100A1 protein expression in human
ailing myocardium in vitro. Given the recent evolution of
ncreasingly efficient gene transfer technologies, which have
laced congestive HF within the reach of gene-based
linical therapy, these promising results provide the neces-
ary insight into the molecular and cellular mechanisms of
100A1 action in isolated cardiomyocytes, building a strong
ationale for its further translation.
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APPENDIX
For an expandedMethods section and supplemental figures and their legends,
please see the online version of this article.
